THE EFFECTS OF VALETTE® ON SKIN AND HAIR: A POST‐MARKETING SURVEILLANCE STUDY
article
OA: closed
CC0
⤵ 4 in-corpus citations
AI-generated summary
A post-marketing surveillance study found Valette, an oral contraceptive, improved skin and hair conditions related to androgens, with significant reductions in greasiness and disorder severity.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
SUMMARY The effects of Valette ® ‐ an oral contraceptive containing ethinyloestradiol 0.03 mg and the antiandrogenic progestogen dienogest 2.0 mg ‐ on the skin and hair were surveyed over 63,474 cycles in 10,718 women in routine gynaecological practice. Improvements were greatest in women with severe or moderate androgen‐related symptoms. After six cycles, <1% of women had severely greasy hair and 6% had moderate greasiness, compared with 11 % and 27% at baseline; fewer hair washes were needed per week. The incidence of severe and moderately greasy skin disorders fell from 16% to <1%, and from 39% to 7.5%, respectively. Self‐assessments indicated less greasy hair and improved greasy skin disorders in 70% and 81% of women, respectively. The overall effect of Valette on the skin and hair was rated very good or good by 87.5% of women. These results confirm previous observations of a beneficial effect of Valette on androgen‐related skin and hair conditions. (Int J Clin Pract 2000; 54(2): 85‐91)
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (4)
- Comparative Pharmacology of Newer Progestogens 1996
- Modulation of ovarian function by an oral contraceptive containing 30 μg ethinyl estradiol in combination with 2.00 mg dienogest 1997
- Double-blind, randomized, placebo controlled study on the effects of the monophasic oral contraceptive containing 30 μg ethinyl estradiol and 2.00 mg dienogest on the hemostatic system 1997
- Klinische Erfassung antiandrogener Effekte von Dienogest 1995
Cited by (4)
- Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate 2008
- Ethinylestradiol/Dienogest in Oral Contraception 2010
- Antiandrogenic progestins for treatment of signs of androgenisation and hormonal contraception 2004
- Prescribing oral contraceptives on cosmetic purpose in adolescents 2004
References (12)
- Comparative Pharmacology of Newer Progestogens via openalex
- Double-blind, randomized, placebo controlled study on the effects of the monophasic oral contraceptive containing 30 μg ethinyl estradiol and 2.00 mg dienogest on the hemostatic system via openalex
- Klinische Erfassung antiandrogener Effekte von Dienogest via openalex
- Modulation of ovarian function by an oral contraceptive containing 30 μg ethinyl estradiol in combination with 2.00 mg dienogest via openalex
- W2329857878 via openalex
- W2471626985 via openalex
- doi:10.1016/0010-7824(92)90128-g via openalex
- doi:10.1016/s0002-9378(12)91814-1 via openalex
- doi:10.1007/bf01849658 via openalex
- doi:10.1515/9783112422168-015 via openalex
- doi:10.1007/bf01849634 via openalex
- W2273715905 via openalex
Cited by (4)
- Ethinylestradiol/Dienogest in Oral Contraception 2010
- Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate 2008
- Antiandrogenic progestins for treatment of signs of androgenisation and hormonal contraception 2004
- Prescribing oral contraceptives on cosmetic purpose in adolescents 2004
Source provenance
- openalex
- last seen: 2026-05-10T10:23:22.614198+00:00
License: CC0
· commercial use OK